Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Parallel, and Active-controlled Phase III Trial

Next Previous
Search
Trial Profile

Compound Edaravone Injection for Acute Ischemic Stroke, a Multi-center, Randomized, Double-blind, Parallel, and Active-controlled Phase III Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Sep 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Borneol/edaravone (Primary) ; Edaravone
  • Indications Stroke
  • Focus Registrational; Therapeutic Use
  • Acronyms TASTE
  • Sponsors Jiangsu Simcere Pharmaceutical

    • Most Recent Events

    • 05 Sep 2024 According to a Simcere Pharmaceutical Group media release, the company announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), has been granted the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Ischemic Stroke (AIS).
    • 24 Mar 2022 According to a Simcere Pharmaceutical Group media release, the data from this trial was published on February 16, 2021 in STROKE, a leading international authoritative medicine journal.
    • 29 Sep 2021 Results of sub-group analysis presented at the Hypertension Scientific Session 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top